ZA200308984B - Taci-immunoglobulin fusion proteins. - Google Patents

Info

Publication number

ZA200308984B

ZA200308984B ZA200308984A ZA200308984A ZA200308984B ZA 200308984 B ZA200308984 B ZA 200308984B ZA 200308984 A ZA200308984 A ZA 200308984A ZA 200308984 A ZA200308984 A ZA 200308984A ZA 200308984 B ZA200308984 B ZA 200308984B

Authority

ZA

South Africa

Prior art keywords

taci

amino acid

immunoglobulin

seq

fusion protein

Prior art date

2001-05-24

Links

• Espacenet
• Global Dossier
• Discuss

• 108020001507 fusion proteins Proteins 0.000 title claims description 135
• 102000037865 fusion proteins Human genes 0.000 title claims description 134
• 102000005962 receptors Human genes 0.000 claims abstract description 44
• 108020003175 receptors Proteins 0.000 claims abstract description 44
• 239000003814 drug Substances 0.000 claims abstract description 23
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 9
• 102000001493 Cyclophilins Human genes 0.000 claims abstract description 9
• 108010068682 Cyclophilins Proteins 0.000 claims abstract description 9
• 239000011575 calcium Substances 0.000 claims abstract description 9
• 229910052791 calcium Inorganic materials 0.000 claims abstract description 9
• 239000012190 activator Substances 0.000 claims abstract description 8
• 125000000539 amino acid group Chemical group 0.000 claims description 150
• 210000004027 cell Anatomy 0.000 claims description 143
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 143
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 127
• 229920001184 polypeptide Polymers 0.000 claims description 122
• 108060003951 Immunoglobulin Proteins 0.000 claims description 94
• 102000018358 immunoglobulin Human genes 0.000 claims description 94
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 62
• 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 61
• 101100537522 Homo sapiens TNFSF13B gene Proteins 0.000 claims description 57
• 150000007523 nucleic acids Chemical class 0.000 claims description 56
• 102000039446 nucleic acids Human genes 0.000 claims description 54
• 108020004707 nucleic acids Proteins 0.000 claims description 54
• 125000003729 nucleotide group Chemical group 0.000 claims description 49
• 239000002773 nucleotide Substances 0.000 claims description 48
• 102000050862 Transmembrane Activator and CAML Interactor Human genes 0.000 claims description 42
• 108700002109 Transmembrane Activator and CAML Interactor Proteins 0.000 claims description 41
• 239000000203 mixture Substances 0.000 claims description 33
• 239000012634 fragment Substances 0.000 claims description 30
• 238000004519 manufacturing process Methods 0.000 claims description 29
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 28
• 239000008194 pharmaceutical composition Substances 0.000 claims description 21
• 206010028980 Neoplasm Diseases 0.000 claims description 17
• 150000001413 amino acids Chemical class 0.000 claims description 16
• 101100369999 Homo sapiens TNFSF13 gene Proteins 0.000 claims description 13
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 13
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 13
• 102100024585 Tumor necrosis factor ligand superfamily member 13 Human genes 0.000 claims description 13
• 239000003937 drug carrier Substances 0.000 claims description 13
• 239000000539 dimer Substances 0.000 claims description 12
• 210000004881 tumor cell Anatomy 0.000 claims description 9
• 230000002401 inhibitory effect Effects 0.000 claims description 6
• 230000035755 proliferation Effects 0.000 claims description 5
• 230000036765 blood level Effects 0.000 claims description 4
• 238000000338 in vitro Methods 0.000 claims description 2
• 230000027455 binding Effects 0.000 abstract description 40
• 239000003446 ligand Substances 0.000 abstract description 18
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract description 6
• 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract description 6
• 230000001976 improved effect Effects 0.000 abstract description 4
• 238000011160 research Methods 0.000 abstract description 2
• 108090000623 proteins and genes Proteins 0.000 description 213
• 102000004169 proteins and genes Human genes 0.000 description 139
• 235000018102 proteins Nutrition 0.000 description 135
• 102000053602 DNA Human genes 0.000 description 84
• 108020004414 DNA Proteins 0.000 description 83
• 238000000034 method Methods 0.000 description 75
• 230000014509 gene expression Effects 0.000 description 47
• 239000002502 liposome Substances 0.000 description 42
• 239000013604 expression vector Substances 0.000 description 40
• 241000699670 Mus sp. Species 0.000 description 38
• 239000013598 vector Substances 0.000 description 38
• 238000003752 polymerase chain reaction Methods 0.000 description 30
• 230000001225 therapeutic effect Effects 0.000 description 30
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 26
• 108010076504 Protein Sorting Signals Proteins 0.000 description 24
• 238000006243 chemical reaction Methods 0.000 description 24
• 229920001223 polyethylene glycol Polymers 0.000 description 24
• 235000001014 amino acid Nutrition 0.000 description 23
• 239000002202 Polyethylene glycol Substances 0.000 description 22
• 239000003795 chemical substances by application Substances 0.000 description 22
• 201000010099 disease Diseases 0.000 description 22
• 239000013612 plasmid Substances 0.000 description 22
• 241000700605 Viruses Species 0.000 description 20
• 238000013459 approach Methods 0.000 description 20
• 241001529936 Murinae Species 0.000 description 19
• 230000000295 complement effect Effects 0.000 description 19
• 239000007924 injection Substances 0.000 description 19
• 238000002347 injection Methods 0.000 description 19
• 206010028417 myasthenia gravis Diseases 0.000 description 19
• 229920000642 polymer Polymers 0.000 description 19
• 230000001105 regulatory effect Effects 0.000 description 19
• 241001465754 Metazoa Species 0.000 description 18
• 230000000694 effects Effects 0.000 description 18
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 18
• 210000002966 serum Anatomy 0.000 description 18
• 238000011282 treatment Methods 0.000 description 18
• 108091028043 Nucleic acid sequence Proteins 0.000 description 17
• 241000701161 unidentified adenovirus Species 0.000 description 17
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 16
• 239000002585 base Substances 0.000 description 16
• 238000013518 transcription Methods 0.000 description 16
• 230000035897 transcription Effects 0.000 description 16
• 108010009685 Cholinergic Receptors Proteins 0.000 description 15
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 15
• 102000034337 acetylcholine receptors Human genes 0.000 description 15
• 108020004999 messenger RNA Proteins 0.000 description 15
• 239000013615 primer Substances 0.000 description 15
• 241000701447 unidentified baculovirus Species 0.000 description 15
• 208000023275 Autoimmune disease Diseases 0.000 description 14
• 150000001720 carbohydrates Chemical class 0.000 description 14
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
• 210000001519 tissue Anatomy 0.000 description 14
• 238000012546 transfer Methods 0.000 description 14
• 108020004705 Codon Proteins 0.000 description 13
• 108020004635 Complementary DNA Proteins 0.000 description 13
• 210000001744 T-lymphocyte Anatomy 0.000 description 13
• 239000003550 marker Substances 0.000 description 13
• 238000000746 purification Methods 0.000 description 13
• 102000004127 Cytokines Human genes 0.000 description 12
• 108090000695 Cytokines Proteins 0.000 description 12
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 238000010804 cDNA synthesis Methods 0.000 description 12
• 239000002299 complementary DNA Substances 0.000 description 12
• 239000000499 gel Substances 0.000 description 12
• 239000003155 DNA primer Substances 0.000 description 11
• 241000588724 Escherichia coli Species 0.000 description 11
• 108091034117 Oligonucleotide Proteins 0.000 description 11
• 235000014633 carbohydrates Nutrition 0.000 description 11
• 238000012217 deletion Methods 0.000 description 11
• 230000037430 deletion Effects 0.000 description 11
• 238000004520 electroporation Methods 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 210000004185 liver Anatomy 0.000 description 11
• 210000004962 mammalian cell Anatomy 0.000 description 11
• 230000001404 mediated effect Effects 0.000 description 11
• 238000010172 mouse model Methods 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 230000007017 scission Effects 0.000 description 11
• 230000003248 secreting effect Effects 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 241000196324 Embryophyta Species 0.000 description 10
• 241001452677 Ogataea methanolica Species 0.000 description 10
• 238000003776 cleavage reaction Methods 0.000 description 10
• 238000010367 cloning Methods 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 238000005516 engineering process Methods 0.000 description 10
• 229920002477 rna polymer Polymers 0.000 description 10
• 208000024891 symptom Diseases 0.000 description 10
• 238000011830 transgenic mouse model Methods 0.000 description 10
• 239000013603 viral vector Substances 0.000 description 10
• 229920003169 water-soluble polymer Polymers 0.000 description 10
• 208000009386 Experimental Arthritis Diseases 0.000 description 9
• 206010018364 Glomerulonephritis Diseases 0.000 description 9
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
• 241000699666 Mus <mouse, genus> Species 0.000 description 9
• 235000013601 eggs Nutrition 0.000 description 9
• 239000003623 enhancer Substances 0.000 description 9
• 239000012528 membrane Substances 0.000 description 9
• 210000003205 muscle Anatomy 0.000 description 9
• 230000035772 mutation Effects 0.000 description 9
• 230000006320 pegylation Effects 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 238000006467 substitution reaction Methods 0.000 description 9
• 208000034172 Autoimmune Experimental Myasthenia Gravis Diseases 0.000 description 8
• 241000699660 Mus musculus Species 0.000 description 8
• 239000000427 antigen Substances 0.000 description 8
• 108091007433 antigens Proteins 0.000 description 8
• 102000036639 antigens Human genes 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 235000018417 cysteine Nutrition 0.000 description 8
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
• 238000012377 drug delivery Methods 0.000 description 8
• 239000012636 effector Substances 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 210000004379 membrane Anatomy 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 206010039073 rheumatoid arthritis Diseases 0.000 description 8
• 238000010561 standard procedure Methods 0.000 description 8
• 241000701022 Cytomegalovirus Species 0.000 description 7
• 206010061218 Inflammation Diseases 0.000 description 7
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
• 239000004472 Lysine Substances 0.000 description 7
• 238000012408 PCR amplification Methods 0.000 description 7
• 108010002747 Pfu DNA polymerase Proteins 0.000 description 7
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 108010022394 Threonine synthase Proteins 0.000 description 7
• 238000005917 acylation reaction Methods 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 239000011324 bead Substances 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 239000007795 chemical reaction product Substances 0.000 description 7
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
• 230000001684 chronic effect Effects 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 210000002683 foot Anatomy 0.000 description 7
• 230000004054 inflammatory process Effects 0.000 description 7
• 239000002480 mineral oil Substances 0.000 description 7
• 235000010446 mineral oil Nutrition 0.000 description 7
• 239000011535 reaction buffer Substances 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 230000002269 spontaneous effect Effects 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 230000003321 amplification Effects 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 206010003246 arthritis Diseases 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 238000010276 construction Methods 0.000 description 6
• 230000034994 death Effects 0.000 description 6
• 230000001900 immune effect Effects 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 6
• 239000004005 microsphere Substances 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 238000003199 nucleic acid amplification method Methods 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 239000008188 pellet Substances 0.000 description 6
• 201000001474 proteinuria Diseases 0.000 description 6
• 238000005932 reductive alkylation reaction Methods 0.000 description 6
• 230000002103 transcriptional effect Effects 0.000 description 6
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 5
• 102000004961 Furin Human genes 0.000 description 5
• 108090001126 Furin Proteins 0.000 description 5
• 241000238631 Hexapoda Species 0.000 description 5
• 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 5
• 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 5
• 208000001647 Renal Insufficiency Diseases 0.000 description 5
• 230000009471 action Effects 0.000 description 5
• 230000010933 acylation Effects 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 150000001299 aldehydes Chemical class 0.000 description 5
• 230000002391 anti-complement effect Effects 0.000 description 5
• 108010008730 anticomplement Proteins 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 229910002091 carbon monoxide Inorganic materials 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
• 150000001875 compounds Chemical class 0.000 description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
• 239000012153 distilled water Substances 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 230000007717 exclusion Effects 0.000 description 5
• 238000000605 extraction Methods 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 102000056239 human TNFRSF13B Human genes 0.000 description 5
• 230000028993 immune response Effects 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 230000001965 increasing effect Effects 0.000 description 5
• 230000001939 inductive effect Effects 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 230000000977 initiatory effect Effects 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 210000003292 kidney cell Anatomy 0.000 description 5
• 208000017169 kidney disease Diseases 0.000 description 5
• 201000006370 kidney failure Diseases 0.000 description 5
• 108020001756 ligand binding domains Proteins 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 102000040430 polynucleotide Human genes 0.000 description 5
• 108091033319 polynucleotide Proteins 0.000 description 5
• 239000002157 polynucleotide Substances 0.000 description 5
• -1 radioisotopes Substances 0.000 description 5
• 238000012552 review Methods 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 230000009870 specific binding Effects 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 230000009261 transgenic effect Effects 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• 108020003589 5' Untranslated Regions Proteins 0.000 description 4
• 102000008186 Collagen Human genes 0.000 description 4
• 108010035532 Collagen Proteins 0.000 description 4
• 208000003456 Juvenile Arthritis Diseases 0.000 description 4
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
• 208000034578 Multiple myelomas Diseases 0.000 description 4
• 206010028372 Muscular weakness Diseases 0.000 description 4
• 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 4
• 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 108020004682 Single-Stranded DNA Proteins 0.000 description 4
• 108010090804 Streptavidin Proteins 0.000 description 4
• 108010006785 Taq Polymerase Proteins 0.000 description 4
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000001004 anti-acetylcholinic effect Effects 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 239000012131 assay buffer Substances 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 244000309464 bull Species 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 229920001436 collagen Polymers 0.000 description 4
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
• 230000006801 homologous recombination Effects 0.000 description 4
• 238000002744 homologous recombination Methods 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 238000011081 inoculation Methods 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 239000007928 intraperitoneal injection Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 229960000485 methotrexate Drugs 0.000 description 4
• 210000000865 mononuclear phagocyte system Anatomy 0.000 description 4
• 230000002232 neuromuscular Effects 0.000 description 4
• 210000003101 oviduct Anatomy 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 229920005989 resin Polymers 0.000 description 4
• 239000011347 resin Substances 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 229960000187 tissue plasminogen activator Drugs 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 230000001131 transforming effect Effects 0.000 description 4
• 239000013638 trimer Substances 0.000 description 4
• 210000002700 urine Anatomy 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• 210000005253 yeast cell Anatomy 0.000 description 4
• 229920000936 Agarose Polymers 0.000 description 3
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
• 108020005544 Antisense RNA Proteins 0.000 description 3
• 208000006820 Arthralgia Diseases 0.000 description 3
• 241001260012 Bursa Species 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 102100035882 Catalase Human genes 0.000 description 3
• 108010053835 Catalase Proteins 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 208000009329 Graft vs Host Disease Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
• 102000014150 Interferons Human genes 0.000 description 3
• 108010050904 Interferons Proteins 0.000 description 3
• 102000018697 Membrane Proteins Human genes 0.000 description 3
• 108010052285 Membrane Proteins Proteins 0.000 description 3
• 108090000157 Metallothionein Proteins 0.000 description 3
• 208000010428 Muscle Weakness Diseases 0.000 description 3
• 206010028851 Necrosis Diseases 0.000 description 3
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
• 108700019146 Transgenes Proteins 0.000 description 3
• 206010052779 Transplant rejections Diseases 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 210000000577 adipose tissue Anatomy 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 238000000246 agarose gel electrophoresis Methods 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• 238000005804 alkylation reaction Methods 0.000 description 3
• 238000003277 amino acid sequence analysis Methods 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 239000003708 ampul Substances 0.000 description 3
• 206010002022 amyloidosis Diseases 0.000 description 3
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
• 108010044715 asialofetuin Proteins 0.000 description 3
• 239000002738 chelating agent Substances 0.000 description 3
• 239000003638 chemical reducing agent Substances 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
• 239000013599 cloning vector Substances 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 230000008021 deposition Effects 0.000 description 3
• 238000001212 derivatisation Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 238000000502 dialysis Methods 0.000 description 3
• 102000004419 dihydrofolate reductase Human genes 0.000 description 3
• 210000002257 embryonic structure Anatomy 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 238000001415 gene therapy Methods 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
• 208000024908 graft versus host disease Diseases 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 239000007943 implant Substances 0.000 description 3
• 229940047124 interferons Drugs 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 125000005647 linker group Chemical group 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 201000008383 nephritis Diseases 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 210000001322 periplasm Anatomy 0.000 description 3
• 150000003904 phospholipids Chemical class 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000003127 radioimmunoassay Methods 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 108091008146 restriction endonucleases Proteins 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 229940104230 thymidine Drugs 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
• KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
• 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
• KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 208000037157 Azotemia Diseases 0.000 description 2
• 108010028006 B-Cell Activating Factor Proteins 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 241000193830 Bacillus <bacterium> Species 0.000 description 2
• 244000063299 Bacillus subtilis Species 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 108020004638 Circular DNA Proteins 0.000 description 2
• 102000000503 Collagen Type II Human genes 0.000 description 2
• 108010041390 Collagen Type II Proteins 0.000 description 2
• 102000014447 Complement C1q Human genes 0.000 description 2
• 108010078043 Complement C1q Proteins 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
• 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 206010012305 Demyelination Diseases 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• 229920004937 Dexon® Polymers 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 206010059866 Drug resistance Diseases 0.000 description 2
• 101150029662 E1 gene Proteins 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 206010014561 Emphysema Diseases 0.000 description 2
• 102100031780 Endonuclease Human genes 0.000 description 2
• 241000701959 Escherichia virus Lambda Species 0.000 description 2
• 108091029865 Exogenous DNA Proteins 0.000 description 2
• 108091006020 Fc-tagged proteins Proteins 0.000 description 2
• 108010067193 Formaldehyde transketolase Proteins 0.000 description 2
• 108090000698 Formate Dehydrogenases Proteins 0.000 description 2
• KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 244000068988 Glycine max Species 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
• 108010003272 Hyaluronate lyase Proteins 0.000 description 2
• 102000001974 Hyaluronidases Human genes 0.000 description 2
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
• 206010021263 IgA nephropathy Diseases 0.000 description 2
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
• 241000235058 Komagataella pastoris Species 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 102000003792 Metallothionein Human genes 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 102000055324 Myelin Proteolipid Human genes 0.000 description 2
• 101710094913 Myelin proteolipid protein Proteins 0.000 description 2
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
• 102000003992 Peroxidases Human genes 0.000 description 2
• 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
• 102100027330 Phosphoribosylaminoimidazole carboxylase Human genes 0.000 description 2
• 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
• 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 2
• 206010037596 Pyelonephritis Diseases 0.000 description 2
• 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
• 108010009460 RNA Polymerase II Proteins 0.000 description 2
• 102000009572 RNA Polymerase II Human genes 0.000 description 2
• 108091027981 Response element Proteins 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• 206010042674 Swelling Diseases 0.000 description 2
• 108700005078 Synthetic Genes Proteins 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
• 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
• 229910052770 Uranium Inorganic materials 0.000 description 2
• 241000700618 Vaccinia virus Species 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 108020005202 Viral DNA Proteins 0.000 description 2
• 108700005077 Viral Genes Proteins 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 230000029936 alkylation Effects 0.000 description 2
• KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 230000003367 anti-collagen effect Effects 0.000 description 2
• 230000003172 anti-dna Effects 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 208000037908 antibody-mediated disorder Diseases 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 125000000837 carbohydrate group Chemical group 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 239000012501 chromatography medium Substances 0.000 description 2
• 208000019069 chronic childhood arthritis Diseases 0.000 description 2
• 208000020832 chronic kidney disease Diseases 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 230000027326 copulation Effects 0.000 description 2
• 229940095074 cyclic amp Drugs 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 229920006237 degradable polymer Polymers 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 238000002567 electromyography Methods 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 208000028208 end stage renal disease Diseases 0.000 description 2
• 201000000523 end stage renal failure Diseases 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 102000036444 extracellular matrix enzymes Human genes 0.000 description 2
• 108091007167 extracellular matrix enzymes Proteins 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 238000005194 fractionation Methods 0.000 description 2
• 238000010230 functional analysis Methods 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 229930182830 galactose Natural products 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 238000003205 genotyping method Methods 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 108010044853 histidine-rich proteins Proteins 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 229960002773 hyaluronidase Drugs 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 208000013403 hyperactivity Diseases 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 239000002955 immunomodulating agent Substances 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• 230000001861 immunosuppressant effect Effects 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 239000012678 infectious agent Substances 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 238000004255 ion exchange chromatography Methods 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 101150066555 lacZ gene Proteins 0.000 description 2
• 238000001638 lipofection Methods 0.000 description 2
• 239000008263 liquid aerosol Substances 0.000 description 2
• 210000005229 liver cell Anatomy 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 230000005291 magnetic effect Effects 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229910021645 metal ion Inorganic materials 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 210000003463 organelle Anatomy 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 238000012261 overproduction Methods 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 238000005192 partition Methods 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 239000013610 patient sample Substances 0.000 description 2
• 238000010647 peptide synthesis reaction Methods 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 108010035774 phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 2
• 239000000906 photoactive agent Substances 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 150000003212 purines Chemical class 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 150000003230 pyrimidines Chemical class 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 238000010532 solid phase synthesis reaction Methods 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 108010087967 type I signal peptidase Proteins 0.000 description 2
• 230000005951 type IV hypersensitivity Effects 0.000 description 2
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
• 241001529453 unidentified herpesvirus Species 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
• FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
• 101150096273 ADE2 gene Proteins 0.000 description 1
• 241001640321 Acossus Species 0.000 description 1
• 241000228431 Acremonium chrysogenum Species 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010025188 Alcohol oxidase Proteins 0.000 description 1
• 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
• 241000710929 Alphavirus Species 0.000 description 1
• 241000428352 Amma Species 0.000 description 1
• 101100437119 Arabidopsis thaliana AUG2 gene Proteins 0.000 description 1
• OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
• 108010002913 Asialoglycoproteins Proteins 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 241001203868 Autographa californica Species 0.000 description 1
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000004736 B-Cell Leukemia Diseases 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
• 241000178270 Canarypox virus Species 0.000 description 1
• 241000222128 Candida maltosa Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
• 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 102100030886 Complement receptor type 1 Human genes 0.000 description 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 206010010264 Condition aggravated Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 1
• 101100229963 Drosophila melanogaster grau gene Proteins 0.000 description 1
• 206010013654 Drug abuse Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
• 102100036509 Erythropoietin receptor Human genes 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 206010015548 Euthanasia Diseases 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 108010020195 FLAG peptide Proteins 0.000 description 1
• XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
• 101150096839 Fcmr gene Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
• 102000000340 Glucosyltransferases Human genes 0.000 description 1
• 108010055629 Glucosyltransferases Proteins 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 108010053070 Glutathione Disulfide Proteins 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 102100020948 Growth hormone receptor Human genes 0.000 description 1
• 101150069554 HIS4 gene Proteins 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
• 241000175212 Herpesvirales Species 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
• 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
• 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
• 102000002265 Human Growth Hormone Human genes 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 239000000854 Human Growth Hormone Substances 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 241001619348 Idris Species 0.000 description 1
• JLWLMGADIQFKRD-QSFUFRPTSA-N Ile-His-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CN=CN1 JLWLMGADIQFKRD-QSFUFRPTSA-N 0.000 description 1
• 108700002232 Immediate-Early Genes Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 108010060231 Insect Proteins Proteins 0.000 description 1
• 102000013691 Interleukin-17 Human genes 0.000 description 1
• 108050003558 Interleukin-17 Proteins 0.000 description 1
• 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
• 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000004889 Interleukin-6 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 102000004890 Interleukin-8 Human genes 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 244000285963 Kluyveromyces fragilis Species 0.000 description 1
• 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
• 241001138401 Kluyveromyces lactis Species 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 208000022435 Light chain deposition disease Diseases 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• 239000006137 Luria-Bertani broth Substances 0.000 description 1
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
• 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
• 101100243377 Mus musculus Pepd gene Proteins 0.000 description 1
• 102000047918 Myelin Basic Human genes 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• 102000003505 Myosin Human genes 0.000 description 1
• 108060008487 Myosin Proteins 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 206010029148 Nephrolithiasis Diseases 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 241000221960 Neurospora Species 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 241000320412 Ogataea angusta Species 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 241001041510 Oxytelinae group Species 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 229920001734 PEG propionaldehyde Polymers 0.000 description 1
• 101150029183 PEP4 gene Proteins 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108091093037 Peptide nucleic acid Proteins 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• IEIFEYBAYFSRBQ-IHRRRGAJSA-N Phe-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N IEIFEYBAYFSRBQ-IHRRRGAJSA-N 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 101710182846 Polyhedrin Proteins 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 108010010974 Proteolipids Proteins 0.000 description 1
• 102000016202 Proteolipids Human genes 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
• 206010037601 Pyelonephritis chronic Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
• 206010048988 Renal artery occlusion Diseases 0.000 description 1
• 206010038378 Renal artery stenosis Diseases 0.000 description 1
• 206010038486 Renal neoplasms Diseases 0.000 description 1
• 108020005091 Replication Origin Proteins 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 239000002262 Schiff base Substances 0.000 description 1
• 150000004753 Schiff bases Chemical class 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
• 108700025832 Serum Response Element Proteins 0.000 description 1
• 241000710960 Sindbis virus Species 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 108010068542 Somatotropin Receptors Proteins 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 206010042573 Superovulation Diseases 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
• 108700026226 TATA Box Proteins 0.000 description 1
• 239000008051 TBE buffer Substances 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 241000906446 Theraps Species 0.000 description 1
• 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
• 102100029337 Thyrotropin receptor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 241000255993 Trichoplusia ni Species 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 101710178302 Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 208000006593 Urologic Neoplasms Diseases 0.000 description 1
• 244000301083 Ustilago maydis Species 0.000 description 1
• 235000015919 Ustilago maydis Nutrition 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 229920002494 Zein Polymers 0.000 description 1
• PCBMGUSDYHYVBQ-SOOFDHNKSA-N [4-amino-2-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazol-5-yl]phosphonic acid Chemical compound P(=O)(O)(O)C=1N=C(NC1N)C1[C@H](O)[C@H](O)[C@H](O1)CO PCBMGUSDYHYVBQ-SOOFDHNKSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000004308 accommodation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 238000003916 acid precipitation Methods 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 108010068380 arginylarginine Proteins 0.000 description 1
• 230000003286 arthritogenic effect Effects 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 229920001718 aryloxy-PEG Polymers 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 229920001743 bis-succinimidyl carbonate PEG Polymers 0.000 description 1
• 238000010504 bond cleavage reaction Methods 0.000 description 1
• WVMHLYQJPRXKLC-UHFFFAOYSA-N borane;n,n-dimethylmethanamine Chemical compound B.CN(C)C WVMHLYQJPRXKLC-UHFFFAOYSA-N 0.000 description 1
• 150000001639 boron compounds Chemical class 0.000 description 1
• RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
• NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
• 239000005388 borosilicate glass Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 229940041514 candida albicans extract Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000023402 cell communication Effects 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 201000006368 chronic pyelonephritis Diseases 0.000 description 1
• 229940047120 colony stimulating factors Drugs 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 108010004073 cysteinylcysteine Proteins 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 238000011033 desalting Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• 229960002986 dinoprostone Drugs 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 230000006334 disulfide bridging Effects 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 150000002061 ecdysteroids Chemical class 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 230000006862 enzymatic digestion Effects 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000001400 expression cloning Methods 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000012224 gene deletion Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 102000035122 glycosylated proteins Human genes 0.000 description 1
• 108091005608 glycosylated proteins Proteins 0.000 description 1
• 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000005090 green fluorescent protein Substances 0.000 description 1
• YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 210000005161 hepatic lobe Anatomy 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 102000055229 human IL4 Human genes 0.000 description 1
• 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000001631 hypertensive effect Effects 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 150000004001 inositols Chemical class 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 201000006334 interstitial nephritis Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 238000011866 long-term treatment Methods 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 229920001427 mPEG Polymers 0.000 description 1
• 229960003511 macrogol Drugs 0.000 description 1
• 238000007885 magnetic separation Methods 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
• 231100000855 membranous nephropathy Toxicity 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000003595 mist Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 230000036473 myasthenia Effects 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• 239000002077 nanosphere Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 201000000173 nephrocalcinosis Diseases 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 230000016087 ovulation Effects 0.000 description 1
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
• 150000002924 oxiranes Chemical class 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 238000012753 partial hepatectomy Methods 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 101150009573 phoA gene Proteins 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
• 208000031223 plasma cell leukemia Diseases 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
• 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
• 108010070958 polyaconitylated human serum albumin Proteins 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920002721 polycyanoacrylate Polymers 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920002704 polyhistidine Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000000734 protein sequencing Methods 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 238000013102 re-test Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 101150079601 recA gene Proteins 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 239000013074 reference sample Substances 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 229960004509 serum gonadotrophin Drugs 0.000 description 1
• 239000004017 serum-free culture medium Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 210000001562 sternum Anatomy 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000013595 supernatant sample Substances 0.000 description 1
• 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• 210000002105 tongue Anatomy 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 239000012137 tryptone Substances 0.000 description 1
• 102000042287 type II cytokine receptor family Human genes 0.000 description 1
• 108091052254 type II cytokine receptor family Proteins 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000003501 vero cell Anatomy 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 239000012138 yeast extract Substances 0.000 description 1
• 239000005019 zein Substances 0.000 description 1
• 229940093612 zein Drugs 0.000 description 1